Four months after one of its scientists was snubbed for a Nobel Prize in medicine, a leading cancer center will ask a court to credit him in another way: by adding his name to patents underlying a major cancer immunotherapy drug made possible by the award-winning research.
Dana-Farber Cancer Institute on Monday will petition the U.S. District Court in Boston to include Gordon Freeman and a colleague on six patents issued by the U.S. Patent Office. Those patents currently name Nobel laureate Tasuku Honjo, two Kyoto University colleagues, and one scientist from the drug maker Ono Pharmaceutical.
About the Author Reprints
